All In Biotech

Drug Trial Radar · NCT05559476

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

A Phase 3, Open-label, Randomized, Controlled, Multicountry Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU HD Vaccine in Adults Aged 65 Years and Above

Last checked: Nov 20, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,029 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,029

Actual

Start

Oct 20, 2022

Primary completion

Mar 7, 2023

Study completion Aug 15, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccineBiological

    RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

  • FLU HD vaccineBiological

    FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
  2. Hemagglutinin Inhibition (HI) Titers for 4 FLU Vaccine Strains Expressed as Group GMTsTime frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)
  3. RSV-B Neutralizing Titers Expressed as Group GMTsTime frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Tempe, Arizona

  • GSK Investigational Site

    Canoga Park, California

  • GSK Investigational Site

    Colton, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Immokalee, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Sandy Springs, Georgia

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Evansville, Indiana

  • GSK Investigational Site

    Mishawaka, Indiana

  • GSK Investigational Site

    Valparaiso, Indiana

  • GSK Investigational Site

    Ames, Iowa

  • GSK Investigational Site

    El Dorado, Kansas

  • GSK Investigational Site

    Methuen, Massachusetts

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Grand Island, Nebraska

  • GSK Investigational Site

    Papillion, Nebraska

  • GSK Investigational Site

    North Las Vegas, Nevada

  • GSK Investigational Site

    Warren Township, New Jersey

  • GSK Investigational Site

    Hickory, North Carolina

  • GSK Investigational Site

    Rocky Mount, North Carolina

  • GSK Investigational Site

    Wilmington, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Edmond, Oklahoma

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Columbia, South Carolina

  • GSK Investigational Site

    North Charleston, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.